X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (294) 294
oncology (250) 250
humans (240) 240
olaparib (230) 230
ovarian cancer (226) 226
olaparib maintenance therapy (196) 196
female (184) 184
poly polymerase (145) 145
cancer (135) 135
chemotherapy (120) 120
mutation (109) 109
ovarian neoplasms - drug therapy (107) 107
homologous recombination (93) 93
open-label (92) 92
breast cancer (89) 89
tumors (86) 86
parp inhibitor (83) 83
dna repair (79) 79
ovarian neoplasms - genetics (75) 75
parp inhibitors (75) 75
care and treatment (69) 69
antineoplastic agents - therapeutic use (65) 65
maintenance therapy (64) 64
poly polymerase inhibitors - therapeutic use (63) 63
ovarian-cancer (62) 62
animals (61) 61
pharmacology & pharmacy (61) 61
double-blind (58) 58
dna damage (57) 57
clinical trials (56) 56
deoxyribonucleic acid--dna (56) 56
breast-cancer (54) 54
research (54) 54
brca (53) 53
fallopian-tube (53) 53
middle aged (51) 51
brca1 protein - genetics (50) 50
cancer therapies (50) 50
monosaccharides (50) 50
sugars (50) 50
aged (47) 47
brca1 (47) 47
ovarian neoplasms - pathology (46) 46
poly polymerase inhibitors - pharmacology (44) 44
repair (44) 44
brca2 protein - genetics (43) 43
phthalazines - therapeutic use (43) 43
piperazines - therapeutic use (43) 43
adult (42) 42
pegylated liposomal doxorubicin (42) 42
health aspects (41) 41
medicine & public health (41) 41
obstetrics & gynecology (41) 41
patients (40) 40
genetic aspects (39) 39
synthetic lethality (39) 39
endocrine system diseases (38) 38
review (38) 38
therapy (38) 38
poly polymerase inhibitors (37) 37
recurrent epithelial ovarian (37) 37
analysis (36) 36
antineoplastic agents - pharmacology (36) 36
carcinoma (35) 35
dna-repair (35) 35
mutations (35) 35
parp (35) 35
ribose (35) 35
dna-damage (34) 34
inhibitors (34) 34
molecular targeted therapy (34) 34
women (34) 34
bevacizumab (33) 33
brca1 protein (33) 33
cell line, tumor (33) 33
drug therapy (33) 33
epithelial ovarian (33) 33
negative breast-cancer (33) 33
carcinoma, ovarian epithelial (32) 32
combination (32) 32
platinum (32) 32
poly polymerases - metabolism (32) 32
somatic mutations (32) 32
genes, brca1 (31) 31
phase-i (31) 31
phthalazines - pharmacology (31) 31
piperazines - pharmacology (31) 31
brca mutation (30) 30
brca2 (30) 30
brca2 mutations (30) 30
medical research (30) 30
survival (30) 30
apoptosis (29) 29
biomarkers (29) 29
hematology, oncology and palliative medicine (29) 29
male (29) 29
antineoplastic combined chemotherapy protocols - therapeutic use (28) 28
multicenter (28) 28
polymerase (28) 28
metastasis (27) 27
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gynecologic Oncology, ISSN 0090-8258, 2017, Volume 144, Issue 3, pp. 486 - 490
Journal Article
BRITISH JOURNAL OF CANCER, ISSN 0007-0920, 12/2015, Volume 113, pp. S1 - S2
Journal Article
Journal Article
ONCOTARGET, ISSN 1949-2553, 07/2017, Volume 8, Issue 27, pp. 43598 - 43599
Journal Article
Molecular cancer therapeutics, ISSN 1535-7163, 01/2019, Volume 18, Issue 1, pp. 89 - 99
Pyrrolobenzodiazepine dimers (PBD) form cross-links within the minor groove of DNA causing double-strand breaks (DSB). DNA repair genes such as BRCA1 and BRCA2... 
DNA-REPAIR DEFECT | DRUG CONJUGATE | CROSS-LINKING AGENT | ONCOLOGY | SEROUS OVARIAN | HOMOLOGOUS RECOMBINATION | OLAPARIB MAINTENANCE THERAPY | PHASE-I | OVARIAN-CARCINOMA | SPECTRUM ANTITUMOR-ACTIVITY | SJG-136 NSC-694501
Journal Article
Nature Genetics, ISSN 1061-4036, 06/2017, Volume 49, Issue 6, pp. 856 - 864
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2016, Volume 140, Issue 3, pp. 443 - 449
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2017, Volume 28, Issue suppl_8, pp. viii57 - viii60
Journal Article
Nature Communications, ISSN 2041-1723, 08/2016, Volume 7, Issue 1, pp. 12425 - 12425
Journal Article
GYNECOLOGIC ONCOLOGY, ISSN 0090-8258, 02/2016, Volume 140, Issue 2, pp. 204 - 209
Objective. To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of veliparib combined with PLD and carboplatin (CD) in patients... 
Thrombocytopenia | POLY(ADP-RIBOSE) POLYMERASE | CLINICAL-TRIAL | PARP inhibitors | DOWN-REGULATION | OLAPARIB MAINTENANCE THERAPY | CHEMOTHERAPY | OBSTETRICS & GYNECOLOGY | 2ND-LINE | CALYPSO TRIAL | RANDOMIZED PHASE-2 | ONCOLOGY | VEGF inhibitors | III TRIAL
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 05/2018, Volume 128, Issue 5, pp. 1727 - 1730
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 02/2019, Volume 152, Issue 2, pp. 270 - 277
The hallmarks of germline(g) and/or somatic(s) BRCA1/2 mutation ovarian cancer (BMOC) patients are increased sensitivity to platinum-based chemotherapy (PCT)... 
Relapse treatment | Chemotherapy | Recurrent ovarian cancer | PARP inhibitors | BRCA mutation | PEGYLATED LIPOSOMAL DOXORUBICIN | MULTICENTER | BEVACIZUMAB | OPEN-LABEL | OLAPARIB MAINTENANCE THERAPY | PACLITAXEL | OBSTETRICS & GYNECOLOGY | ONCOLOGY | RECURRENT | DOUBLE-BLIND | TREATMENT RESPONSE | CARCINOMA | Cancer patients | Genetic aspects | Ovarian cancer | Cancer | Index Medicus
Journal Article
Current opinion in obstetrics & gynecology, ISSN 1040-872X, 02/2019, Volume 31, Issue 1, pp. 4 - 11
Purpose of review This review will provide an update of recently presented clinical data as well as discuss ongoing trials focused on the incorporation of poly... 
poly (ADP-ribose) polymerase | ovarian cancer | BEVACIZUMAB | FUTURE | MAINTENANCE THERAPY | PARP INHIBITOR | OBSTETRICS & GYNECOLOGY | BRCA | OLAPARIB | homologous recombination | DOUBLE-BLIND | RUCAPARIB | CARCINOMA | Women | Enzyme inhibitors | Dosage and administration | Research | Drug therapy | Health aspects | Ovarian cancer
Journal Article
Expert review of anticancer therapy, ISSN 1473-7140, 06/2019, Volume 19, Issue 6, pp. 437 - 446
: The landscape of poly (ADP-ribose) polymerase (PARP) inhibition in ovarian cancer is rapidly evolving and becoming increasingly complex. Ovarian cancer is... 
Rucaparib | ovarian cancer | SAFETY | PARP inhibitor | synthetic lethality | MECHANISMS | OLAPARIB MONOTHERAPY | MAINTENANCE THERAPY | ONCOLOGY | DOUBLE-BLIND | RESISTANCE | HOMOLOGOUS RECOMBINATION | CARCINOMA | EXPRESSION | GERMLINE BRCA1/2 MUTATION
Journal Article
Oncology (Williston Park, N.Y.), ISSN 0890-9091, 07/2018, Volume 32, Issue 7, pp. 339 - 343
Poly(ADP-ribose) polymerase (PARP) proteins are used by cells in several DNA repair processes. PARP inhibition can result in preferential death of cancer cells... 
MULTICENTER | ONCOLOGY | RECURRENT | SAFETY | MUTATION CARRIERS | POLYMERASE INHIBITOR | PHASE-3 TRIAL | DOUBLE-BLIND | OPEN-LABEL | OLAPARIB MAINTENANCE THERAPY | CHEMOTHERAPY | Chemotherapy | Development and progression | Drug therapy | Health aspects | Drug approval | Ovarian cancer | Cancer | Index Medicus
Journal Article
DNA Repair, ISSN 1568-7864, 03/2019, Volume 75, pp. 48 - 59
Poly(ADP ribose) polymerase 1 (PARP1) is a multifunctional DNA repair protein of the base excision repair pathway and plays a major role in the repair of DNA... 
Cancer biomarkers | Isotope-dilution mass spectrometry | Overexpression | PARP1 | DNA repair proteins | DNA damage | MULTICENTER | OPEN-LABEL | PHASE-2 | HUMAN BREAST-CANCER | OLAPARIB MAINTENANCE THERAPY | DAMAGE | RIBOSYLATION | GENETICS & HEREDITY | TOXICOLOGY | INHIBITORS | HALLMARKS | EXPRESSION | Index Medicus
Journal Article